Author Topic: Fulminant hepatitis associated w/Echovirus 25 during Ocrevus treatment...  (Read 36 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8216
  • MS diagnosed 1980
  • Location: Pacific Northwest
I may be giving too much attention to rare, anecdotal instances of adverse effects of the MS disease-modifying drugs, but here is another one. This MS patient was taking Ocrevus but ended up getting a liver transplant--and stopping the Ocrevus.  This is from JAMA Neurology (April 8, 2019), "Fulminant hepatitis associated with Echovirus 25 during treatment with ocrelizumab for multiple sclerosis":


http://bit.ly/2WXuNQ6


This is from the discussion:


Quote
Because ocrelizumab is a novel, high-efficacy disease-modifying therapy for MS, it will probably be extensively used. However, it may impair clearance of enterovirus infections via B-cell depletion. Thus, in the case of compatible symptoms, tests should be conducted for enteroviruses. Given the bimodal clinical presentation (ie, the patient had a severe rebound of liver enzyme levels after initial improvement), patients receiving ocrelizumab with enteroviral infection need close follow-up.

MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline ewizabeth

  • Trailblazer
  • *
  • Posts: 588
I was required to get tested for all forms of hepatitis prior to starting Ocrevus so now I know why. I was completely negative on all of them.

 

Related Topics

  Subject / Started by Replies Last post
1 Replies
102 Views
Last post April 06, 2016, 10:01:36 am
by agate
1 Replies
102 Views
Last post June 14, 2017, 10:35:24 am
by agate
0 Replies
98 Views
Last post August 01, 2017, 08:26:08 am
by agate
0 Replies
90 Views
Last post August 01, 2017, 08:28:52 am
by agate
0 Replies
69 Views
Last post February 19, 2018, 07:47:49 am
by agate